A clinical study of TCR-based immunotherapies product for solid cancer.
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2018
Price : $35 *
At a glance
- Drugs T cell receptor based immunotherapy Zelluna Immunotherapy (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- 26 Mar 2018 New trial record
- 19 Mar 2018 According to an Orgenesis media release, Zelluna Immunotherapy plans to initiate this study in 2019.